Lead Product(s): Insulin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ORMD-0801
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Oramed has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH). The trial will measure efficacy endpoints via MRI-PDFF for 12-weeks dosing.